Ablaze Pharmaceuticals
China
- Shanghai
- 29/11/2021
- Series A
- $75,000,000
Ablaze Pharma is a clinical stage Biopharmaceutical Company which is focused on the developing innovative Targeted Radiotherapy (TRT) to benefit cancer patients in China.
- Industry Pharmaceutical Manufacturing
- Website http://www.ablazepharma.com/
- LinkedIn https://www.linkedin.com/company/ablaze-pharmaceuticals-shanghai-co-ltd/
Related People
Tiecheng Alex QiaoFounder
United States -
San Diego, California,
Serial Entrepreneur experienced in high tech start ups. Twenty years of extensive knowledge in managing complex technologies and technology product development. A proven track record of conceiving and growing companies from concept to successful market entry, developing new product concepts, sourcing and managing co-development activities both in US and in China. Demonstrated success in building and leading multi-functional teams, strategic planning, and decision making. Also an inventor with 25 issued US patents and experience in developing and managing Intellectual Property.
Specialties: Conceiving and developing high tech business from concept to commercial success. Team building in high tech start up companies. Integrated product development and commercialization.
Navier AI | $6,500,000 | (Dec 17, 2025)
AIR Platforms | $6,100,000 | (Dec 17, 2025)
Auxira Health | $7,800,000 | (Dec 17, 2025)
Mirelo AI | $41,000,000 | (Dec 17, 2025)
Lucis (YC X25) | $8,500,000 | (Dec 17, 2025)
Verisoul | $8,800,000 | (Dec 17, 2025)
Aeovian Pharmaceuticals | $55,000,000 | (Dec 17, 2025)
Nanit | $50,000,000 | (Dec 17, 2025)
Culture Biosciences | Undisclosed Amount | (Dec 17, 2025)
YSE Beauty | $15,000,000 | (Dec 17, 2025)
Vital Lyfe | $24,000,000 | (Dec 17, 2025)
Dux Security | $9,000,000 | (Dec 17, 2025)